Company intelligence / Profile preview

K Pharma, Inc.

Minato-ku, Tokyo, Japankdpharmagroup.com ↗

Ownership: Private
Development stage: Commercial

Overview

K Pharma is a Japanese biotech company spun out from Keio University School of Medicine. It specializes in iPS cell-based drug discovery and regenerative medicine targeting CNS disorders. The company has completed a successful Phase 1/2a trial for an iPS-derived therapy in ALS with plans to advance to Phase 3. Additional programs target spinal cord injuries and cerebral infarctions using both small molecule drugs identified via iPS models and direct regenerative approaches.

Therapeutic areas: Neurology
Modalities: Induced pluripotent stem (iPS) cell-based therapiesSmall moleculesRegenerative medicine products
Industry: Biotech

Drug pipeline

11 assets

ropinirole (K Pharma, Inc.)

Approved

10 more assets in the full pipeline.

Request access →

Partnerships

AlfresaKeio University School of Medicine

Beyond the preview

Go deeper on K Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K Pharma, Inc..

Explore the full profile